Interesting trivia for anybody who also owned Lynx
and came across Axaron. It is old information, but
I got a kick out of it. Was trying to find
Biofrontera_Discovery patents and stumbled on this.
Opposition to DEPD® patent rejected
Leverkusen, June 10, 2002
Biofrontera's patent on its high-resolution gene expression analysis procedure DEPD® remains unmodified in the granted form. This is the decision of the German patent office which overruled objections raised in 1999 by Axaron (former BASF Lynx). This decision strengthens Biofrontera's strong patent position in basic technology for the discovery of new "drug targets" and the characterization of new drugs.
The strength of this technology is underlined by Biofrontera's latest success in identifying, validating and finally patent filing for a series of differentially regulated potential "drug targets" in the indications of "chronic pain" and "stroke". For some of these "drug targets" Biofrontera is already developing test systems, or new compounds as candidates for innovative medicinal products.
Furthermore, Biofrontera has recognized that a large number of genes correlate with the examined diseases. This insight gives Biofrontera an improved understanding of biochemical processes causing the development and course of the diseases, allows innovative research and development programs. Based on DEPD® results in the indications Parkinson's disease and epilepsy, further patent applications will follow shortly, and research and development programs will be initiated.
Biofrontera Pharmaceuticals (www.biofrontera.com) is a drug discovery and development company that focuses on neurological, psychiatric, and inflammatory or neuroinflammatory disorders. Biofrontera's proprietary high-resolution gene expression profiling technology (DEPD®) is complemented with in-house state-of-the-art bioinformatics, and a broad range of preclinical target identification, validation and lead optimization tools.
Biofrontera has an unusually well balanced project portfolio, with a first project in Phase II clinical trials. Additional research projects are at various stages of preclinical development, lead finding and optimization, or target identification and validation.
....................
Also interesting is what is going on with Biofrontera
and DNAPrint. Dnag.ob is down a lot recently and traded
quite a few shares today, fwiw. |
